Not a good buy right now for an impatient buyer: momentum is still bearish (MACD negative/expanding) and the stock is trading below the key pivot (1.272) with earnings (Feb 9 pre-market) as a near-term binary catalyst.
Price is sitting near support (S1 ~1.131). Downside to S2 (1.044) is meaningful if earnings disappoint, while upside faces layered resistance (1.272, 1.414, 1.501).
Options positioning is aggressively call-heavy, but implied volatility is extremely elevated (IV percentile ~94), implying “expensive” optionality and heightened event-risk pricing.
Overall: Avoid new entries until price reclaims the pivot/turns trend-positive; if already holding, this is a high-risk hold into earnings rather than an add.
Technical Analysis
Trend/Momentum: MACD histogram is negative (-0.00253) and worsening (negatively expanding) → bearish momentum remains in control.
RSI: RSI(6) ~43.1 (neutral-to-weak) → not oversold enough to suggest a strong mean-reversion buy.
Moving averages: Converging MAs → suggests a potential base, but no confirmed upside trend.
Key levels: Pivot 1.272 (must reclaim for a more constructive setup); Resistance R1 1.414 then R2 1.501; Support S1 1.131 then S2 1.044.
Probabilistic pattern read: Similar-pattern study implies modest negative drift (next day -0.11%, next week -1.16%, next month -3.26%).
Sentiment (positioning): Extremely call-skewed (OI put/call 0.13; volume put/call 0.06) → traders are positioned more bullish/speculative than bearish.
Volatility: 30D IV ~157.75 vs historical vol ~68.89; IV percentile ~94.42 → options market is pricing very large moves (often around catalysts like earnings).
Activity: Today volume 401; today volume vs 30D avg ~50.89 (very elevated). Open interest also elevated (today vs OI avg ~138.96) → heightened attention/positioning.
Takeaway: Options flow looks bullish, but the very high IV suggests the market expects turbulence; this supports “event-driven” risk rather than a clean technical buy setup.
Technical Summary
Sell
3
Buy
10
Positive Catalysts
could improve focus and profitability mix.
Neutral/Negative Catalysts
Earnings catalyst imminent: QDEC 2025 earnings on 2026-02-09 pre-market → high probability of a sharp move, and current trend is not supportive.
Technicals still bearish: Negative and expanding MACD + price below pivot increases odds of a breakdown to S1/S2 if results/guide disappoint.
Business deterioration signals: Recent quarter showed revenue contraction and margin compression (see financials), which can overwhelm “asset sale” optimism.
Wall Street skepticism: Neutral rating with reduced price target highlights limited confidence in extracting value from the portfolio.
Financial Performance
Latest quarter: 2026/Q1.
Revenue: 367.883M, down -6.77% YoY → top-line contraction persists.
Profitability: Gross margin 18.18%, down -9.69% YoY → margin pressure is worsening.
Bottom line: Net income -20.625M (loss), “improved” YoY by 4.89% but still materially negative; EPS -0.23 improved 4.55% YoY but remains a loss.
Growth read: This is not a growth profile right now; improvements are incremental while sales and margins are trending the wrong way.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent change: (2025-11-14) DA Davidson cut price target to $1.50 from $2.00 and maintained Neutral.
Rationale summary: Skeptical that the strategic review can unlock substantial value after years of underinvestment; competitive landscape crowded with emerging brands.
Wall Street pros: Potential upside if divestitures/strategic review materially improve profitability and simplify the story.
Wall Street cons: Ongoing brand/portfolio competitiveness issues, shrinking revenue, margin compression, and limited confidence that restructuring alone can fix the core trajectory.
Influential/political trading: No recent congress trading data available; hedge funds and insiders show neutral activity (no notable recent trend).
Wall Street analysts forecast HAIN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HAIN is 3.25 USD with a low forecast of 1.5 USD and a high forecast of 5 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast HAIN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HAIN is 3.25 USD with a low forecast of 1.5 USD and a high forecast of 5 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
3 Hold
0 Sell
Moderate Buy
Current: 1.180
Low
1.5
Averages
3.25
High
5
Current: 1.180
Low
1.5
Averages
3.25
High
5
DA Davidson
Neutral
downgrade
$2
AI Analysis
2025-11-14
Reason
DA Davidson
Price Target
$2
AI Analysis
2025-11-14
downgrade
Neutral
Reason
DA Davidson lowered the firm's price target on Hain Celestial to $1.50 from $2 and keeps a Neutral rating on the shares. Amidst the company's ongoing strategic review, the firm is skeptical there is much value to be extracted from a portfolio that for too long was starved of investment, the analyst tells investors in a research note. Hain Celestial once stood as the vanguard for the health and wellness revolution, but it has been lapped by a vast array of emerging brands amidst increased consumer awareness and lower barriers to entry, the firm added.
Barclays
Andrew Lazar
Equal Weight
downgrade
$2
2025-09-17
Reason
Barclays
Andrew Lazar
Price Target
$2
2025-09-17
downgrade
Equal Weight
Reason
Barclays analyst Andrew Lazar lowered the firm's price target on Hain Celestial to $1.50 from $2 and keeps an Equal Weight rating on the shares. The firm updated the company's model post the fiscal Q4 earnings report.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for HAIN
